Editor’s Note The 48th San Antonio Breast Cancer Symposium (SABCS) was held in San Antonio, USA, from December 9 to 12, 2025. A retrospective study led by Professor Mao Xiaoyun…

Editor’s note: For patients with HER2-positive breast cancer, neoadjuvant treatment strategies are rapidly evolving—from traditional dual HER2 blockade to the fast-emerging era of antibody–drug conjugates (ADCs). Recently, Chinese-developed anti-HER2 ADCs…

Editor’s Note: Estrogen receptor (ER)–positive breast cancer has long been regarded as a relatively “indolent” subtype. However, during disease progression, a subset of patients experience loss of ER expression, converting…

Editor’s Note As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

Editor’s Note: As CDK4/6 inhibitors (CDK4/6i) secure their role in adjuvant therapy for HR+/HER2− early breast cancer, a central clinical challenge has emerged: how to maximize benefit while minimizing toxicity…

Editor’s Note: In recent years, systemic treatment options for HER2-positive breast cancer brain metastases have made meaningful progress, yet substantial unmet clinical needs remain. At the 2025 San Antonio Breast…

Editor's Note: HER2-positive breast cancer has a high incidence of brain metastases. In the era when treatment relied primarily on local therapies, patient survival outcomes were poor. The PERMEATE study…